Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Novartis Investigative Site, Budapest

Novartis Investigative Site, Debrecen

Novartis Investigative Site, Taipei

Novartis Investigative Site, Bangkok

Novartis Investigative Site, Rozzano

Novartis Investigative Site, Milan

Novartis Investigative Site, Edirne

Novartis Investigative Site, Madrid

Novartis Investigative Site, Madrid

Novartis Investigative Site, Madrid

Novartis Investigative Site, Toulouse

Novartis Investigative Site, Istanbul

Novartis Investigative Site, Istanbul

Novartis Investigative Site, Izmir

Sarah Cannon Research Institute SCRI RC, Nashville

Novartis Investigative Site, Bologna

Novartis Investigative Site, Modena

Novartis Investigative Site, Essen

Novartis Investigative Site, Tainan City

Novartis Investigative Site, Paris

University of Texas MD Anderson Cancer Center MD Anderson PSC, Houston

Novartis Investigative Site, Napoli

Novartis Investigative Site, Ulm

Novartis Investigative Site, Songkhla

Novartis Investigative Site, Villejuif

Oregon Health and Science University SC-10, Portland

Novartis Investigative Site, El Achrafiyé

The Sidney Kimmel Cancer Center at Johns Hopkins Hospital Johns Hopkins, Baltimore

Massachusetts General Hospital, Boston

Huntsman Cancer Institute Univ. of Utah HCI, Salt Lake City

Novartis Investigative Site, Toronto

Novartis Investigative Site, Jena

Novartis Investigative Site, Amsterdam

Novartis Investigative Site, Leiden

Novartis Investigative Site, Oslo

Novartis Investigative Site, Gdansk

Novartis Investigative Site, Poznan

Novartis Investigative Site, Rzeszów

Novartis Investigative Site, Warsaw

Novartis Investigative Site, Barcelona

Novartis Investigative Site, Adana